A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis

Plaque Psoriasis Clinical Trial

— 197-002  

Official title:

A Single-Center, Randomized, Blinded, Vehicle- Controlled Exploratory Study to Assess the Activity of CRx-197 in Subjects With Plaque Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00796211
• Other study ID #: CRx-197-002
• Status: Completed
• Phase: Phase 2
• First received: November 21, 2008
• Last updated: January 14, 2009
• Start date: November 2008
• Est. completion date: January 2009

Study information

• Verified date: January 2009
• Source: Zalicus
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

This will be a phase 2a single-center, randomized, blinded, vehicle-controlled exploratory study to assess the activity and safety of CRx-197 in subjects with plaque psoriasis. Approximately 20 male or female subjects with chronic plaque type psoriasis, 18 to 70 years of age, will be included in this study.

All subjects with stable psoriatic plaques will receive all of the following treatments each in a separate test field, once each day for four weeks under occlusion:

• CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)

• CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)

• 0.1% nortriptyline HCl topical cream

• 0.005% calcipotriol topical cream

• Vehicle of CRx-197 topical cream (placebo)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: January 2009
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• I01 Subject must voluntarily sign and date the written informed consent prior to any study specific procedures

• I02 Subject must be 18 to 70 years of age

• I03 Subject must have chronic plaque psoriasis and plaque infiltrates of a thickness of a minimum of 150 µm and stable plaques in an area sufficient for up to five test fields and an untreated control field per each plaque

• I04 Subject must be free from a condition/disease that the investigator feels interferes with the interpretation of the study results.

• I05 Females of childbearing potential age should either be surgically sterile (hysterectomy or tubal ligation), or should use a highly effective medically accepted contraceptive regimen.

Exclusion Criteria:

• E01 Erythrodermic, guttate or pustular psoriasis

• E02 Cardiac disease, including recent myocardial infarction, any degree of heart block or other cardiac arrhythmias or valvular heart disease

• E03 Mania or acute delirium or epilepsy

• E04 Narrow angle glaucoma

• E05 Hyperthyroidism by medical history, TSH less than LLN, or a subject receiving thyroid medication

• E06 Diabetes

• E07 Intolerance to lidocaine

• E08 Severe liver disease [ALT laboratory value that exceeds 2.5x ULN]

• E09 Known severe kidney disease, acute urinary retention, prostatic hypertrophy with post void residual urine or laboratory value of creatinine that exceeds 1.5x ULN

• E10 Significant gastrointestinal disease including but not limited to pyloric stenosis or paralytic ileus

• E11 Inflammatory dermatoses except psoriasis; bacterial, viral, or fungal skin infections (at the test plaques); facial rosacea

• E12 Active varicella, tuberculosis, syphilis or post-vaccine reactions

• E13 Autoimmune disease other than plaque psoriasis (e.g., lupus erythematosis)

• E14 Known allergic reactions or hypersensitivity to any of the components of the study treatments

• E15 Allergy to adhesives on the templates used in this study

• E16 UV therapy or significant UV exposure in the four weeks before treatment application

• E17 History of malignancy (except for treated or excised basal cell carcinoma)

• E18 History of drug or alcohol abuse (as defined by the Investigator)

• E19 Symptoms of a clinically significant illness in the four weeks before treatment application that may influence the outcome of the study

• E20 Subject with demonstrated hypercalcemia (calcium greater than ULN) or evidence of Vitamin D toxicity

• E21 Subject with demonstrated hypokalemia (less than LLN)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Drug:
• CRx-197
CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
• CRx-197
CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
• Nortriptyline
0.1% nortriptyline HCl topical cream
• Calcipotriol
0.005% calcipotriol topical cream

Other:
• Placebo
Vehicle of CRx-197 topical cream (placebo)

Locations

Country	Name	City	State
Germany	ProInnovera	Muenster

Sponsors (1)

Lead Sponsor	Collaborator
Zalicus

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability as assessed by treatment emergent adverse events, physical exams, vital signs, concomitant medications/procedures and subject assessment of pruritus		6 weeks	Yes
Secondary	Difference in change from baseline in psoriatic infiltrate measured by ultrasound at Days 8, 15, 22, 29 and 43 between CRx-197, nortriptyline, active comparator as well as vehicle of CRx-197 and untreated test field(s)		6 weeks	No
Secondary	Differences in change from baseline in erythema measured by chromametry at Days 8, 15, 22, 29 and 43 between CRx-197, nortriptyline, active comparator, vehicle of CRx-197, untreated test field(s) and normal skin		6 weeks	No
Secondary	Modified PASI at Baseline, and Days 8, 15, 22, 29 and 43 between CRx-197, nortriptyline, active comparator, vehicle of CRx-197, untreated test field(s)		6 weeks	No